{
    "clinical_study": {
        "@rank": "149542", 
        "arm_group": [
            {
                "arm_group_label": "Fimasartan 60mg", 
                "arm_group_type": "Experimental", 
                "description": "60mg/day of Fimasartan will be oral administered for the study period (8 weeks)"
            }, 
            {
                "arm_group_label": "Atenolol 50mg", 
                "arm_group_type": "Active Comparator", 
                "description": "50mg/day of Atenolol will be oral administered for the study period (8 weeks)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the antihypertensive efficacy and changes of\n      neurohormonal markers of fimasartan and atenolol with exaggerated blood pressure response\n      during exercise in essential hypertensive patients."
        }, 
        "brief_title": "Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients", 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "detailed_description": {
            "textblock": "After subjects have signed informed consent voluntarily, when they are taking hypertension\n      medication, they go through screening period for 7 days including wash-out period.\n\n      After screening and wash-out period, subjects take the placebo for 14 days (Maximum 21\n      days), and evaluate their suitability to Inclusion and Exclusion criteria.\n\n      Patients, who evaluated the proper subject for this clinical trial, are allocated to\n      experimental group (Fimasartan 60mg) or Control group (Atenolol 50mg) randomly at a ratio\n      1:1 and their investigational drugs will be administered daily for the study period (8\n      weeks). Subjects visit their investigators twice during treatment period, when they take\n      their investigational drugs for 4 weeks, and 8 weeks.\n\n      The placebo period will be single-blinded and the treatment allocation in this study will be\n      double-blinded."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subjects who agreed to participate in this clinical trial and submitted the written\n             informed consent\n\n          2. Subjects aged 20 to 75 years\n\n          3. Essential hypertension patients who are measured more 140mmHg, less than 170mmHg of\n             sitting systolic blood pressure(SiSBP) or more 90mmHg, less than 110mmHg of sitting\n             diastolic blood pressure(SiDBP) at baseline(Day 0)\n\n          4. men who are measured more 210mmHg, women who are measured more 190mmHg or increasing\n             more than 50mmHg after exercise at baseline(Day 0)\n\n          5. Subject who considered to understand this clinical trial, be cooperative,and able to\n             be followed-up whole of the clinical trial period\n\n        Exclusion Criteria:\n\n          1. Patients who are measured the difference of mean blood pressure of one arm under\n             sitting diastolic blood pressure(SiDBP) 10mmHg or SiSBP 20mmHg at screening and\n             baseline visit\n\n          2. more 170mmHg of mean Sitting systolic blood pressure(SiSBP)or more 110mmHg of mean\n             Sitting diastolic blood pressure(SiDBP) before exercise at baseline(Day 0)\n\n          3. Patients with secondary hypertension\n\n          4. Patients with orthostatic hypotension who has sign and symptom\n\n          5. Patients with severe insulin dependent or uncontrolled diabetes mellitus (HbA1c>9,\n             regimen change of oral hypoglycemic agent, using insulin)\n\n          6. Patients with severe heart disease, ischemic heart disease within 6 months,\n             peripheral vascular disease, Percutaneous transluminal coronary angiography(PTCA),\n             Coronary artery bypass graft(CABG)\n\n          7. Patients with significant ventricular tachycardia, atrial fibrillation, atrial\n             flutter or other significant arrhythmia\n\n          8. Patients with hypertrophic obstructive cardiomyopathy, severe obstructive coronary\n             artery disease, aortic stenosis, hemodynamically significant aortic valve or mitral\n             valve disease\n\n          9. Patients with severe cerebrovascular disease\n\n         10. Patients with known severe or malignancy retinopathy\n\n         11. Patients with wasting disease, autoimmune disease, connective tissue disease at\n             present and/or previous\n\n         12. Patients with significant investigations; abnormal renal function (Creatinine more\n             1.5 times than upper limit of normal), abnormal liver function(AST, ALT more 2 times\n             than upper limit of normal), severe fatty liver disease needed medication\n\n         13. Patients with surgical and medical disease that is able to be affect to absorption,\n             distribution, metabolism and excretion\n\n         14. Patients who have a story or evidence of alcohol or drug abuse within 2 years\n\n         15. Childbearing and breast-feeding women\n\n         16. Female who plan to become pregnancy or have a possibility of pregnancy but don't\n             prevent conception with acknowledged methods\n\n         17. Patients with Bronchial Asthma\n\n         18. Patients expected to live less than 1 year with tumor or chronic disease\n\n         19. Patients with hepatitis B or C\n\n         20. Patients with history of allergic reaction to any angiotensin II antagonist\n\n         21. Patients who took medicine within 12 weeks from screening visit or is going on the\n             progress of other clinical trial\n\n         22. Subject who are judged unsuitable to participate in this clinical trial by\n             investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01736488", 
            "org_study_id": "BR-FA-CT-401"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fimasartan 60mg", 
                "description": "Fimasartan 60mg", 
                "intervention_name": "Fimasartan", 
                "intervention_type": "Drug", 
                "other_name": "Kanarb"
            }, 
            {
                "arm_group_label": "Atenolol 50mg", 
                "description": "Atenolol 50mg", 
                "intervention_name": "Atenolol", 
                "intervention_type": "Drug", 
                "other_name": "Tenolmin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antihypertensive Agents", 
                "Atenolol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hypertension", 
            "Antihypertensive efficacy", 
            "Neurohormonal markers", 
            "Blood Pressure Response", 
            "Exercise"
        ], 
        "lastchanged_date": "May 28, 2013", 
        "location": {
            "contact": {
                "email": "sk2ang@yuhs.ac", 
                "last_name": "Sun Kyung Kang, CRC", 
                "phone": "+82-2-2228-8229"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "120-752"
                }, 
                "name": "Severance Hospital"
            }, 
            "investigator": {
                "last_name": "Jong Won Ha, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Phase IV Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients", 
        "overall_contact": {
            "email": "shlee07@boryung.co.kr", 
            "last_name": "Seong Hee Lee, Director", 
            "phone": "+82-2-708-8069"
        }, 
        "overall_contact_backup": {
            "email": "kminlee@boryung.co.kr", 
            "last_name": "Min Lee Kim, CRA", 
            "phone": "+82-2-708-8065"
        }, 
        "overall_official": {
            "affiliation": "Yonsei University", 
            "last_name": "Jong Won Ha, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To compare the difference of sitting Systolic Blood Pressure(SiSBP) at the peak compared to at resting between Fimasartan 60mg group and Atenolol 50mg group", 
            "measure": "The difference of sitting Systolic Blood Pressure(SiSBP) between at the peak compared to at resting", 
            "safety_issue": "Yes", 
            "time_frame": "After 8 weeks from baseline visit"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01736488"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To compare the difference of sitting Diastolic Blood Pressure(SiDBP), Heart Rate, Neurohormonal markers at the peak compared to at resting between Fimasartan 60mg group and Atenolol 50mg group", 
                "measure": "The difference of sitting Diastolic Blood Pressure(SiDBP) at the peak compared to at resting", 
                "safety_issue": "Yes", 
                "time_frame": "After 8 weeks from baseline visit"
            }, 
            {
                "description": "To compare the difference of sitting Systolic Blood Pressure(SiSBP), sitting Diastolic Blood Pressure(SiDBP), Heart Rate at each exercising stage and at recovery compared to at resting between Fimasartan 60mg group and Atenolol 50mg group", 
                "measure": "The difference of sitting Systolic Blood Pressure(SiSBP) at each exercising stage  compared to at resting", 
                "safety_issue": "Yes", 
                "time_frame": "After 8 weeks from baseline visit"
            }, 
            {
                "description": "To compare the difference of sitting Systolic Blood Pressure(SiSBP), sitting Diastolic Blood Pressure(SiDBP), Heart Rate, neurohormonal markers among at resting, each exercising stage and recovery between Fimasartan 60mg group and Atenolol 50mg group", 
                "measure": "The difference of sitting Systolic Blood Pressure(SiSBP) among at resting, each exercising stage and recovery", 
                "safety_issue": "Yes", 
                "time_frame": "After 8 weeks from baseline visit"
            }
        ], 
        "source": "Boryung Pharmaceutical Co., Ltd", 
        "sponsors": {
            "collaborator": {
                "agency": "Severance Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Boryung Pharmaceutical Co., Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}